Literature DB >> 6247969

Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.

H J Field, G Darby.   

Abstract

Mice infected with three different isolates of herpes simplex virus (HSV) and treated with acyclovir (acycloguanosine; ACV) showed low levels of virus replication during the acute phase of infection. However, virus isolated from such treated mice did not show increased resistance to ACV. In contrast, resistant virus was readily isolated in vitro by passaging HSV in the presence of the drug. The degree of resistance was determined, in part, by the nature of the cells used to test the virus. The majority of ACV-resistant strains induced low or undetectable levels of HSV-specified thymidine kinase (TK), the enzyme responsible for phosphorylating ACV in infected cells. The TK-resistant strains were attenuated when injected into mice as indicated by reductions in virus replication, inflammation, and establishment of latent infections in sensory ganglia. The reduced virulence of the TK- strains was most marked after intracerebral inoculation, where the lethal dose was increased more than 100-fold compared with the parental isolates. However, one mutant is described which induced high levels of TK but was highly resistant to ACV and retained virulence for mice.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6247969      PMCID: PMC283760          DOI: 10.1128/AAC.17.2.209

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Immunological response restricts number of cells in sensory ganglia infected with herpes simplex virus.

Authors:  M A Walz; H Yamamoto; A L Notkins
Journal:  Nature       Date:  1976-12-09       Impact factor: 49.962

2.  Deoxypyrimidine kinases of herpes simplex viruses types 1 and 2: comparison of serological and structural properties.

Authors:  M E Thouless; P Wildy
Journal:  J Gen Virol       Date:  1975-02       Impact factor: 3.891

3.  Low virulence and immunogenicity in mice and in rabbits of variants of Herpes simplex virus resistant to 5-iodo-2-deoxyuridine.

Authors:  M A Marcialis; P La Colla; M L Schivo; O Flore; A Firinu; B Loddo
Journal:  Experientia       Date:  1975-04-15

4.  Possible peptide chain termination mutants in thymide kinase gene of a mammalian virus, herpes simplex virus.

Authors:  W P Summers; M Wagner; W C Summers
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

5.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

6.  Induction capacity and influence of dThdMP on thymidine kinase activity of type 1 and 2 strains of herpes simplex virus.

Authors:  S Dundarov; D Dundarova; S Todorov; L Kavaklova; D Falke
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

7.  Serological properties of thymidine kinase produced in cells infected with type 1 or type 2 herpes virus.

Authors:  M E Thouless
Journal:  J Gen Virol       Date:  1972-12       Impact factor: 3.891

8.  A virus-specific thymidine kinase in BHK-21 cells infected with herpes simplex virus.

Authors:  H G Klemperer; G R Haynes; W I Shedden; D H Watson
Journal:  Virology       Date:  1967-01       Impact factor: 3.616

9.  Herpes keratitis in rabbits: pathogenesis and effect of antiviral nucleosides.

Authors:  G E Underwood; G A Elliott; D A Buthala
Journal:  Ann N Y Acad Sci       Date:  1965-07-30       Impact factor: 5.691

10.  Acute and recurrent infection with herpes simplex virus in the mouse: a model for studying latency and recurrent disease.

Authors:  T J Hill; H J Field; W A Blyth
Journal:  J Gen Virol       Date:  1975-09       Impact factor: 3.891

View more
  61 in total

Review 1.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.

Authors:  M N Ellis; P M Keller; J A Fyfe; J L Martin; J F Rooney; S E Straus; S N Lehrman; D W Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 4.  Prophylaxis for genital herpes. Should it be used routinely?

Authors:  A Mindel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

6.  Demonstration of viral thymidine kinase inhibitor and its effect on deoxynucleotide metabolism in cells infected with herpes simplex virus.

Authors:  L M Nutter; S P Grill; G E Dutschman; R A Sharma; M Bobek; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

7.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant.

Authors:  D J Goldstein; S K Weller
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

Review 8.  Persistent herpes simplex virus infection and mechanisms of virus drug resistance.

Authors:  H J Field
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

9.  Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats.

Authors:  M G Kaplitt; J G Tjuvajev; D A Leib; J Berk; K D Pettigrew; J B Posner; D W Pfaff; S D Rabkin; R G Blasberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 10.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.